The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease.
about
Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic reviewEarly effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.What's new in the pathology, pathophysiology and management of benign esophageal disorders?Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersEffect of itopride, a new prokinetic, in patients with mild GERD: a pilot study.Emerging treatments for irritable bowel syndrome.Pharmacology of serotonin: what a clinician should know.Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteersDifferences in the Control of Secondary Peristalsis in the Human Esophagus: Influence of the 5-HT4 Receptor versus the TRPV1 Receptor.Strategy for treatment of nonerosive reflux disease in AsiaEffect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humansDrug-induced Liver Injury Associated with Mosapride Citrate: A Report of Two Cases.New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.New and future drug development for gastroesophageal reflux disease.Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.Buspirone, a new drug for the management of patients with ineffective esophageal motility?Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease.Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.Therapeutic effects of mosapride citrate and lansoprazole for prevention of aspiration pneumonia in patients receiving gastrostomy feeding.Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole aloneCauses of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease.Early effect of oral administration of omeprazole with mosapride as compared with those of omeprazole alone on the intragastric pH.Circumferential and axial distribution of esophageal mucosal damage in reflux disease.Effects of mosapride on esophageal functions and gastroesophageal reflux.Effects of mosapride on esophageal motor activity and esophagogastric junction compliance in healthy volunteers.Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.Engineering of a novel optimized platform for sublingual delivery with novel characterization tools: in vitro evaluation and in vivo pharmacokinetics study in human.The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.Use of biorelevant media for assessment of a poorly soluble weakly basic drug in the form of liquisolid compacts: in vitro and in vivo study.
P2860
Q27026890-38AB6D49-3C4B-4635-8D87-FD413DEFC95FQ33480299-E45C76C8-7B42-418F-A2A7-E2EA41A70A93Q33815326-4ACB3C5C-8E03-499E-8306-F6A3F50F88C4Q34026230-BF5DFFDA-76F5-4992-8EF8-DC6626F05133Q34166903-1C5E4662-C250-45A3-A42D-F81D749C8808Q34433818-9D76D969-965E-431D-8F10-A2A32C00AF7CQ34482014-88607DFC-AFD6-428E-9E6C-79B5532290BCQ35596862-088A0BF5-57CE-4DB8-A7E6-EF768FABBA96Q35771441-6EFF55AF-E74C-4261-9CAB-CC6B731D6969Q36082796-AD23466B-E88A-469B-9162-AFC667DD7F4BQ37174645-59E917D1-0D7D-4C36-9F47-CE8DE835DA6CQ37230841-A6D316B1-E6F8-49CD-A416-BD983F724F27Q37647432-8FA95BC6-12C4-4866-80B8-7BC2A5B05AFEQ37735172-DF4598FD-2FB4-4741-85CD-11B311D444D0Q37959240-D4745BF7-AD43-4D91-8237-B5609861E282Q38182103-D1F24EDC-A0E0-4EF2-93CE-F5846685014AQ38696256-7034A3A5-3126-42AE-9DFC-4A6680167065Q38988907-9EEF099B-848B-4F28-8D2F-F4C2B8AA165CQ39205057-8D2DD1B3-A67A-4050-956B-8F290C15419BQ39234924-EA534398-123B-44CA-9FB0-AF7CF0F6D09CQ39682981-E9BEB506-CE64-4BA5-8835-551E08308D36Q40264531-680F5A16-7CB4-4363-8F7A-C2E704AC8BC6Q41072536-06F2E2D0-8F61-41F1-AE15-74026FF38E70Q41172426-D4D2DA04-CCA1-44E8-BD9D-21FA82760F76Q42053790-9C51A1A8-FFE0-4954-A1B1-A00B8232C565Q42145475-B443AD95-9B43-46F1-BE08-F23B1C03D027Q42512754-56885066-BBED-4B41-95FB-5F53DF9CEB57Q42995641-4A0D45BF-AC4C-44D3-A99D-F51E22B871C0Q46109724-C84EEF5B-151F-450C-B0E7-83E29898FE00Q46889718-21F47C50-BA9F-4A13-9682-B2C05C8B1DFAQ48034281-23842EF6-D611-4744-85ED-E20658C4BA3EQ51552807-AB331D5D-1A4F-4AD8-818D-926FF17AD2EDQ53841389-46324884-AFF6-4397-B36C-99B405B9B982
P2860
The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@en
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@nl
type
label
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@en
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@nl
prefLabel
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@en
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@nl
P2093
P2860
P1476
The effect of mosapride, a nov ...... ro-oesophageal reflux disease.
@en
P2093
P2860
P356
10.1046/J.1365-2036.1998.00268.X
P407
P577
1998-01-01T00:00:00Z